Fabienne Hermitte
General Counsel chez VERACYTE, INC.
Profil
Fabienne Hermitte is the founder of HalioDx SASU, founded in 2015, and QIAGEN Marseille SA, founded in 1999.
At QIAGEN Marseille SA, she held the title of Director-Research & Development from 1999 to 2010.
Currently, she is the Senior VP-Global Quality & Regulatory Affairs at Veracyte, Inc. since 2021.
Dr. Hermitte received an undergraduate degree from Institut de Formation Supérieure BioMédicale in 1997, a doctorate from AgroParisTech, and a graduate degree from Faculté de Médecine Paris.
Postes actifs de Fabienne Hermitte
| Sociétés | Poste | Début |
|---|---|---|
| VERACYTE, INC. | General Counsel | 01/08/2021 |
Anciens postes connus de Fabienne Hermitte
| Sociétés | Poste | Fin |
|---|---|---|
HalioDx SASU
 HalioDx SASU BiotechnologyHealth Technology Part of HalioDxinvest SAS, HalioDx SASU is a French company that offers a comprehensive suite of biomarker services to deliver integrated and interpreted data, uncovering the critical biomarkers that drive effective decision-making. The private company is based in Marseille, France. The company's services include outsourcing assays such as NGS, qPCR, ELISA, IHC, and IVD testing to Veracyte. The company also offers Immunogram, a service that integrates multi-omic data sets into a single per patient view of key biomarker signatures specific to their own TME. Additionally, Veracyte, a unique multiplex tissue imaging and analysis approach, combines multiple technologies to characterize the tumor microenvironment. The company was founded in 2014 by Vincent Fert, who has been the CEO since 2014. | Founder | 01/08/2021 |
| QIAGEN MARSEILLE | Founder | - |
Formation de Fabienne Hermitte
| Institut de Formation Supérieure BioMédicale | Undergraduate Degree |
| AgroParisTech | Doctorate Degree |
| Faculté de Médecine Paris | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| VERACYTE, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
QIAGEN Marseille SA
 QIAGEN Marseille SA Miscellaneous Commercial ServicesCommercial Services QIAGEN Marseille SA is a molecular diagnosis company, which focuses on the development and marketing of diagnostic tests in the field of oncology. Its products are used for diagnosis, prognosis and monitoring of patients with leukemia. The company was founded by Vincent Fert, Stéphane Debono, and Fabienne Hermitte on September 23, 1999 and is headquartered in Marseille, France. | Commercial Services |
HalioDx SASU
HalioDx SASU BiotechnologyHealth Technology Part of HalioDxinvest SAS, HalioDx SASU is a French company that offers a comprehensive suite of biomarker services to deliver integrated and interpreted data, uncovering the critical biomarkers that drive effective decision-making. The private company is based in Marseille, France. The company's services include outsourcing assays such as NGS, qPCR, ELISA, IHC, and IVD testing to Veracyte. The company also offers Immunogram, a service that integrates multi-omic data sets into a single per patient view of key biomarker signatures specific to their own TME. Additionally, Veracyte, a unique multiplex tissue imaging and analysis approach, combines multiple technologies to characterize the tumor microenvironment. The company was founded in 2014 by Vincent Fert, who has been the CEO since 2014. | Health Technology |
